Phase 4
Completed N=720
Study Evaluating Etanercept in the Treatment of Subjects With Psoriasis
Source: ClinicalTrials.gov NCT00195507 ↗Enrolled (actual)
720
Serious AEs
—
Results posted
May 2010
Primary outcomePrimary: Physician Global Assessment of Psoriasis (PGA) Score - Mean Value Over 54 Weeks — 1.98; 2.51 units on scale — p=<0.001
Summary
This study will provide a direct comparison of 'continuous therapy' and 'intermittent therapy' with withdrawal and retreatment upon return of psoriasis.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Physician Global Assessment of Psoriasis (PGA) Score - Mean Value Over 54 Weeks |
1.98; 2.51 | <0.001 sig |
| SECONDARY Patient Global Assessment of Psoriasis Score - Percentage of Improvement From Baseline |
57.03; 40.92 | <0.001 sig |
| SECONDARY Time to Achieve a Physician Global Assessment of Psoriasis Score of "Clear" or "Almost Clear" |
127; 168 | — |
| SECONDARY Number of Patients With Survey Response of "Somewhat Satisfied" or Better |
70; 80; 231; 198 | 0.143 |
Eligibility Criteria
Inclusion Criteria
- Stable, active plaque psoriasis
- Failure to respond to the following systemic therapies: Methotrexate, Cyclosporine, PUVA or Fumarate
Exclusion Criteria
- Evidence of skin conditions other than psoriasis that would interfere with evaluations of the effect of the study
- Systemic psoriasis therapy within 28 days prior
Data sourced from ClinicalTrials.gov (NCT00195507). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.